FDA authorizes Abbott's wearable to monitor ketone and glucose in diabetes patients

{
  "signal_id": "ecaf1a4f-172a-97c2-654f-264378a1bd0d",
  "signal_type": "news",
  "signal_subtype": "integrates_with",
  "detected_at": "2026-08-26T15:16:38+00:00",
  "company": {
    "name": "Abbott",
    "domain": "abbott.com"
  },
  "data": {
    "url": "https://www.thehindu.com/sci-tech/health/fda-authorizes-abbotts-wearable-to-monitor-ketone-and-glucose-in-diabetes-patients/article71393502.ece/amp/",
    "title": "FDA authorizes Abbott's wearable to monitor ketone and glucose in diabetes patients - The Hindu",
    "excerpt": "The U.S. Food and Drug Administration said on Tuesday it authorised ​Abbott Laboratories' glucose monitor, making it the first ‌device that continuously monitors both ketone levels ​and blood sugar. Here are ⁠some details: The device branded as Libre Duo 10 Day is designed for a 10-day ‌wear period for people aged 2 years and older living with diabetes. The biowearable is designed to ‌alert ⁠people of rising ketones that can ⁠lead to a diabetic ketoacidosis (DKA) emergency, a serious health complication for people with diabetes. Unlike earlier ketone tests ​that offered ‌only separate, one-time readings, Abbott's device continuously monitors both ketone and glucose levels, displaying real-time trends. The device can send automatic ‌alerts, which may help patients and ​caregivers recognize rising ketones before DKA becomes a medical emergency. \"If glucose is ⁠the speedometer, ketones are like the check engine light - providing an alert that something ‌may need attention,\" said Chris Scoggins, executive vice president of Abbott's diabetes care business. The device brings both glucose and ketone levels together in a single dashboard, providing a more complete picture to ‌help people with diabetes make more informed decisions, ​added Scoggins. Abbott is working with leading pump companies to enable automated insulin ⁠delivery systems to connect with the sensors. ⁠The company said...",
    "product": "Libre Duo 10 Day",
    "summary": "Abbott Laboratories expects its Libre Duo 10 Day device to integrate with devices from Insulet in 2027.",
    "planning": true,
    "image_url": "https://th-i.thgim.com/public/incoming/zb1vpl/article71393514.ece/alternates/FREE_1200/CCI_UDHindu_KSL_UHT7HIRHD_R1593096802_3_e859d1a3-43e2-4034-87cd-f668f6f3d745.jpg",
    "confidence": 0.9,
    "product_data": {
      "name": "Libre Duo 10 Day",
      "full_text": "Libre Duo 10 Day",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-08-26T15:16:38Z",
    "effective_date": "2027-01-01",
    "article_sentence": "The company said the device integrates with the Libre app and expects ‌Libre Duo 10 Day to work with devices from Insulet and Tandem ​in 2027.",
    "related_company_name": "Insulet",
    "related_company_domain": "insulet.com"
  }
}

curl https://signals.autobound.ai/v1/signals/ecaf1a4f-172a-97c2-654f-264378a1bd0d \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"abbott.com","limit":20}'